Physician profile
Robert M Hagood
NPI 1851315550
$8,636.60
in general payments reported to CMS, 2019-2025
35 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,816 · 2020: $2,037 · 2021: $365 · 2022: $457 · 2023: $1,561 · 2024: $178 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.03 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,784.53 | 2019-2023 | Da Vinci Surgical System |
| Heron Therapeutics, INC. | $1,900.00 | 2020 | |
| Tela Bio, INC. | $528.46 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $497.89 | 2019-2025 | Phasix Mesh |
| Allergan, INC. | $487.32 | 2019-2022 | |
| Conmed Corporation | $210.96 | 2023 | Airseal |
| Ethicon US, LLC | $174.90 | 2019-2025 | Echelon Flex, Enseal, Surgicel Nu-Knit |
| Medtronic, INC. | $113.25 | 2021 | |
| Abbvie INC. | $98.86 | 2023-2024 | |
| Integra Lifesciences Corporation | $78.02 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Cumberland Pharmaceuticals, INC. | $77.33 | 2019-2023 | Caldolor |
| C. R. Bard, INC. & Subsidiaries | $74.25 | 2025 | Phasix Mesh |
| Kerecis Limited | $49.11 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Bard Access Systems, INC. | $48.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $46.44 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $41.96 | 2019-2022 | |
| Solventum Corporation | $39.63 | 2025 | Activ.A.C., Prevena, V.A.C. Veraflo Cleanse Choice |
| Kci USA, INC. | $34.43 | 2019 | |
| Merck Sharp & Dohme LLC | $33.28 | 2019-2022 | |
| Innocoll Pharmaceuticals Limited | $27.87 | 2022 | |
| Atricure, INC. | $25.19 | 2022 | |
| Z-Medica, LLC | $24.58 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $24.18 | 2025 | |
| Sanara Medtech INC. | $23.02 | 2022 | |
| Mallinckrodt Enterprises LLC | $22.49 | 2019 | |
| Shire North American Group INC | $21.91 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $20.77 | 2019 | |
| Edwards Lifesciences Corporation | $20.22 | 2022 | |
| La Jolla Pharmaceutical Company | $19.13 | 2024 | Giapreza |
| Dilon Technologies, INC. | $17.62 | 2023 | Hemoblast Bellows |
| Portola Pharmaceuticals, LLC | $16.53 | 2019 | |
| Advanced Oxygen Therapy INC. | $15.70 | 2023 | Topical Oxygen Chamber For Extremities |
| Smith+Nephew, INC. | $15.13 | 2019 | |
| Acell, INC. | $12.31 | 2019 | |
| Acera Surgical, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hagood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.